Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cassava Sciences Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.54 (market cap $5.07B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 106.2× Cassava Sciences Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FLNA | |
|---|---|---|
Market Cap | $5.07B | $47.75M |
Sector | Health | Health |
52-Week High | $29.41 | $4.64 |
52-Week Low | $20.06 | $0.87 |
Enterprise Value | $4.19B | -$34.93M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
